Beam Therapeutics Inc (BEAM): Debts to Book Capitalization

Brandmark of Beam Therapeutics Corp (BEAM)

Beam Therapeutics Inc. (BEAM) business is not subject to GDP influence, as the success of R&D projects depends on science, and the current indicator is 0.22. This price chart illustrates the performance of a company creating a "genetic eraser" to eliminate point mutations. The strategy relies on precision DNA correction without chain breaks, enabling the treatment of hereditary liver and blood pathologies.

Beam Tx (BEAM) - Debts to Book Value from 07/04/2022 to 10/29/2026

Summary analytical data breakdowns for Beam Therapeutics Inc (BEAM)

- price and consensus price forecast:
Stock Price Beam Therapeutics Inc.|BEAM - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Beam Tx|BEAM - Total Company Value
- book capitalization data:
Book Value per Share Beam Therapeutics|BEAM - Total Stockholders' Equity|Market Capitalization to Book Value Ratio beamtx.com|BEAM - Company Total Assets
- debt and liquidity data:
Debt to Equity Beam Therapeutics Inc.|BEAM - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Beam Therapeutics Corp|BEAM - Aggregate Debt Obligations|Debt to Book Value Beam Tx|BEAM - Amount of Long-Term Liabilities|Company Short-Term Debts Beam Therapeutics
Analysis of all company metrics:BEAM Beam Therapeutics Inc.
Manufactured products of Beam Tx

Beam Therapeutics Inc. (BEAM) maintains stability through licensing revenues from pharmaceutical behemoths, which minimizes reliance on external borrowing while developing Base Editing technologies. This metric calculates the ratio of total liabilities to net asset value, allowing an assessment of the balance between debt load and equity via the company's financial leverage trajectory to determine default risks.

Competitors of Beam Therapeutics Inc.

Debts to Book Capitalization TEM (Tempus AI Inc)|Debts to Book Capitalization qiagen.com QGEN|IONS - Debts to Book Capitalization|RGEN - Debt to Book Capitalization Ratio|Debts to Book Capitalization RNA|CRISPR (CRSP) - Debts to Book Value|WGS (GeneDx Holdings Corp.) - Debts to Book Capitalization|Debts to Book Capitalization RARE|Debt to Book Capitalization Ratio SRPT (Sarepta)|Debt to Book Value Twist Bioscience Inc TWST|Debt to Book Value 10x Genomics Corp|NTLA - Debt to Net Assets Ratio|Debt to Book Value Stoke Therapeutics STOK|BLFS - Debt to Book Capital|Debts to Book Capitalization Wave Life Sciences Ltd. WVE|Maze Therapeutics, Inc. (MAZE) - Debt to Net Assets Ratio|Debts to Book Capitalization SION (Sionna Pharma)|Debts to Book Value PRME|Taysha Gene Therapies (TSHA) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio uniqure.com (QURE)|Debts to Book Capitalization MGTX (MeiraGTx)|REGENXBIO Inc - Debts to Book Capitalization|Debt to Book Capitalization Ratio Solid Bio|OCGN - Debts to Book Capitalization Ratio|Debts to Book Capitalization PACB|Debts to Book Value benitec.com|DSGN (Design Therapeutics, Inc.) - Debt to Book Value|Debts to Book Capitalization Rocket Pharma (RCKT)|Debt to Book Value 4D Molecular Therapeutics Inc|Debt to Book Capital lexeotx.com (LXEO)|Debts to Book Capitalization KRRO|Debts to Net Assets editasmedicine.com EDIT|SLN: Debts to Book Capitalization|PRQR: Debt to Book Value|codexis.com - Debt to Book Capitalization Ratio|Debts to Net Assets Sangamo BioSciences|NAUT - Debt to Book Value|Debt to Net Assets Ratio metagenomi.co|DTIL (Precision BioSciences, Inc.) - Debts to Book Capitalization|Debts to Net Assets GBIO (generationbio.com)|BOLD - Debt to Book Capitalization Ratio|Debt to Book Value Ratio Exicure Inc. XCUR|IMNN: Debts to Book Capitalization|Phio Pharmaceuticals (PHIO) - Debt to Book Value|mustangbio.com - Debt to Book Value|TransCode Therapeutics, Inc. (RNAZ) - Debts to Net Assets|Debts to Book Capitalization Bionano Genomics Inc.|Debt to Book Capitalization Ratio Applied DNA Corp|bluebird bio, Inc. - Debts to Book Capitalization|Debts to Book Value immunoprecise.com (IPA)|Debts to Book Capitalization OMGA (Omega Therapeutics, Inc.)|Singular Genomics Systems, Inc. - Debts to Book Capitalization|RGLS: Debt to Book Capitalization Ratio|SYRS - Debt to Book Value|Debts to Book Capitalization Telesis Bio, Inc.|TCON (traconpharma.com) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio Unity Biotechnology, Inc. (UBX)